临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 53-16-7

Estrone

中文名称:雌酚酮
CAS号:53-16-7
分子式: C18H22O2 分子量: 270.37
产品形式: free base
研发状态: Not yet recruiting
研发用途: Metastatic Breast Cancer
研究机构: Mary D Chamberlin; Dartmouth-Hitchcock Medical Center
研发日期: May-24
研发阶段: Phase 1
Estrone is an estrogenic hormone.

CAS: 53123-88-9

Rapamycin (AY-22989)

中文名称:雷帕霉素
CAS号:53123-88-9
分子式: C51H79NO13 分子量: 914.18
产品形式: free base
研发状态: Not yet recruiting
研发用途: Familial Adenomatous Polyposis
研究机构: University Hospital Toulouse
研发日期: August 1 2024
研发阶段: Phase 2
Rapamycin (AY-22989, Rapamune, Sirolimus, NSC-2260804,AY-22989) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

CAS: 53-06-5

Cortisone

中文名称:可的松
CAS号:53-06-5
分子式: C21H28O5 分子量: 360.44
产品形式: Free Base
研发状态: Recruiting
研发用途: Alzheimer Disease; Dementia
研究机构: University of Miami; Shipley Foundation; Dreem
研发日期: March 1 2023
研发阶段: Not Applicable
Cortisone is a pregnane steroid hormone and one of main substance released by the body as a reaction to stress. It suppresses the immune system, thus reducing inflammation and attendant pain and swelling at the site of the injury.

CAS: 53-03-2

Prednisone (NSC-10023)

中文名称:泼尼松
CAS号:53-03-2
分子式: C21H26O5 分子量: 358.43
产品形式: free base
研发状态: Not yet recruiting
研发用途: Cancer; Cancer Metastatic
研究机构: University of Calgary
研发日期: July 1 2024
研发阶段: Phase 2 : Phase 3
Prednisone (NSC-10023, Adasone) is a synthetic corticosteroid agent that is particularly effective as an immunosuppressant compound.

CAS: 5291-32-7

Eprenetapopt (APR-246)

CAS号:5291-32-7
分子式: C10H17NO3 分子量: 199.25
产品形式: free base
研发状态: Completed
研发用途: Bladder Cancer; Gastric Cancer; Non Small Cell Lung Cancer; NSCLC; Urothelial Carcinoma; Advanced Solid Tumor
研究机构: Aprea Therapeutics
研发日期: June 25 2020
研发阶段: Phase 1 : Phase 2
Eprenetapopt (APR-246, PRIMA-1MET) is a small organic molecule that has been shown to restore tumour-suppressor function primarily to mutant p53 and also to induce cell death in various cancer types. APR-246 induces apoptosis and autophagy.

CAS: 52-90-4

L-cysteine

中文名称:L-半胱氨酸
CAS号:52-90-4
分子式: C3H7NO2S 分子量: 121.16
产品形式: free base
研发状态: Recruiting
研发用途: Cystinuria
研究机构: University of California San Francisco
研发日期: May 2 2025
研发阶段: Phase 2
Cysteine is a naturally occurring, sulfur-containing amino acid which is important for protein synthesis, detoxification, and also exerts diverse metabolic functions.